OCGN
NASDAQOcugen Inc.
Price$1.26-0.02 (-1.95%)
01:30 PM07:45 PM
News · 26 weeks55-87%
2025-12-142026-06-07
Mix3090d
- SEC Filings12(40%)
- Other12(40%)
- Earnings3(10%)
- Analyst2(7%)
- Insider1(3%)
Latest news
25 items- SECOcugen Inc. filed SEC Form 8-K: Leadership Update8-K - Ocugen, Inc. (0001372299) (Filer)
- PROcugen to Participate in Upcoming June Investor and Industry ConferencesMALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in June 2026. Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference Date: Thursday, June 4, 2026 Time: 2:30pm EDT Clinical Trials at the Summit 2026 Location: Fontainebleau Las VegasDate: Saturday, June 13, 2026Time: 10:19 – 10:39 am PDTInherited Retinal Diseases: Transforming the Future Through InnovationModerator: Peter KaiserPanelists: Lance Baldo, Pau
- SECOcugen Inc. filed SEC Form 8-K: Leadership Update, Other Events8-K - Ocugen, Inc. (0001372299) (Filer)
- SECOcugen Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Ocugen, Inc. (0001372299) (Filer)
- PROcugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior NotesMALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of $130.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), including the full exercise by the initial purchaser of its option to purchase an additional $15.0 million aggregate principal amount of the notes. The sale of the notes is expected to result in approximately $112.6 million in ne
- PROcugen to Participate in Upcoming May Scientific and Investor ConferencesMALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific and investor conferences in May 2026. Retina World Congress Inherited and Rare Retinal Diseases SessionModerators: Kourous A. Rezaei, MD and Rishi P. Singh, MD, FASRSLocation: Grand BallroomDate: Thursday, May 14, 2026Time: 10:31 am – 11:10 a.m. EDT Stifel 2026 Virtual Ophthalmology Forum Location: VirtualDate: Tuesday, May 26, 2026 Time: 10:30 am – 10:55 a.m. EDT A webcast of the Stife
- SECOcugen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Ocugen, Inc. (0001372299) (Filer)
- SECOcugen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Ocugen, Inc. (0001372299) (Filer)
- PROcugen Provides Business Update with First Quarter 2026 Financial ResultsConference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p<0.05) 31% reduction in lesion size and 27% EZ preservation (correlated to visual function) in optimal dose for Phase 3 About 20% of patients demonstrated no progression of disease and 75% of subjects showed > 30% reduction in Iesion growth compared to control, with a favorable safety and tolerability profileAllows robust registrational Phase 3 trial design, a potential combined U.S./EU trial with 300 subjects, with adaptive design powered at over 95% Trial enrollment complete for OCU400 for retinitis p
- PROcugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior NotesMALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen") (NASDAQ:OCGN) today announced the pricing of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Ocugen also granted the initial purchaser of the notes a 13-day option to purchase up to an additional $15 million aggregate principal amount of the notes. The sale of the notes to the initial purchaser is expected to close on May 7, 2026, subject to customary closing conditions, and is expected to result in approximate
- SECOcugen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Ocugen, Inc. (0001372299) (Filer)
- PROcugen Announces Private Offering of $115 Million of Convertible Senior NotesMALVERN, Pa., May 04, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced its intention to offer, subject to market conditions and other factors, $115 million aggregate principal amount of Convertible Senior Notes due 2034 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Ocugen also expects to grant the initial purchaser of the notes a 13-day option to purchase up to an additional $15 million aggregate principal amount of the notes. The offerin
- PROcugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial ResultsMALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's first quarter 2026 financial results and provide a business update at 8:30 a.m. ET on Tuesday, May 5, 2026. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 4973685Webcast: Available on the events section of the Ocugen
- SECSEC Form DEFA14A filed by Ocugen Inc.DEFA14A - Ocugen, Inc. (0001372299) (Filer)
- SECSEC Form DEF 14A filed by Ocugen Inc.DEF 14A - Ocugen, Inc. (0001372299) (Filer)
- PROcugen to Present at April 2026 Investor and Industry ConferencesMALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at Oppenheimer's 3rd Annual Innovation on the Island Biotech Summit from April 27-29, 2026 in Rio Grande, Puerto Rico; and Abhi Gupta, MBA, Executive Vice President, Commercial and Business Development at Ocugen will present at the 2026 Cell & Gene Meeting on the Mediterranean being held April 28-30, 2026 in Rome, Italy. "I look forward to sharing our story with new audiences and building enthusiasm f
- SECSEC Form PRER14A filed by Ocugen Inc.PRER14A - Ocugen, Inc. (0001372299) (Filer)
- SECSEC Form PRE 14A filed by Ocugen Inc.PRE 14A - Ocugen, Inc. (0001372299) (Filer)
- SECSEC Form SCHEDULE 13G filed by Ocugen Inc.SCHEDULE 13G - Ocugen, Inc. (0001372299) (Subject)
- PRBiotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated CellsAVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related DiseaseIssued on behalf of Avaí Bio, Inc.Companies mentioned in this article: Avaí Bio, Inc. (OTCQB:AVAI), Lineage Cell Therapeutics, Inc. (NYSE:LCTX), Ocugen, Inc. (NASDAQ:OCGN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Longeveron Inc. (NASDAQ:LGVN)Key Takeaways:Avaí Bio (OTCQB:AVAI) and its joint venture partner Austrianova announced on April 7, 2026, that they will present their latest data from their α-Klotho anti-aging therapy at the Second Annual Klotho Conference in September, alongside Dr. Makoto Kuro-o — the physician-scientist widely recognized for discovering the Klotho gene [1
- INSIDERSEC Form 4 filed by Zhang Junge4 - Ocugen, Inc. (0001372299) (Issuer)
- PROcugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt DiseaseGARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time modifier gene therapy for all ABCA4-associated retinopathies MALVERN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that dosing has been successfully completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate developed for all Stargardt disease (ABCA4-associated retino
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ocugen Inc.SCHEDULE 13G/A - Ocugen, Inc. (0001372299) (Subject)
- SECOcugen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Ocugen, Inc. (0001372299) (Filer)
- SECOcugen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Ocugen, Inc. (0001372299) (Filer)
OCGN FAQ
7 questionsWhat does Ocugen Inc. do?
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema...Where does OCGN stock trade?
Ocugen Inc. (OCGN) is listed on NASDAQ.What sector and industry is OCGN in?
Ocugen Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Ocugen Inc. go public?
Ocugen Inc. (OCGN) completed its IPO in 2014.What are analysts saying about OCGN?
Ocugen Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $1200.00 price target on 2026-03-17. Recent price targets range from $350.00 to $1200.00.What companies are similar to OCGN?
Notable peers in the same industry include ISEE (IVERIC bio Inc.), CTIC (CTI BioPharma Corp. (DE)), OTLK (Outlook Therapeutics Inc.), GOSS (Gossamer Bio Inc.), BXRX (Baudax Bio Inc.). Compare OCGN side-by-side with any of them on Quantisnow.How can I track OCGN on Quantisnow?
Quantisnow aggregates Ocugen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OCGN to receive live email and push alerts on every new disclosure.